Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
With
Exelixis
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
AML by current WHO diagnostic criteria, any FAB type (except APML), Refractory ALL, Accelerated/blast phase CML and Refractory MDS with total IPSS score of 2 or higher
ECOG performance status \<= 2
Accessible for treatment, PK sample collection and required study follow-up
Total Bilirubin ≤ 1.5 x ULN and ALT, AST ≤ 3 x ULN
You may not be if
Women who are pregnant or breastfeeding
Subjects with Acute Promyelocytic leukemia disease or CNS leukemia disease)
Hyperleukocytosis (defined as peripheral WBC \>50,000/uL)
Treatment with any other investigational agent for any indication within 30 days of protocol enrollment
Subjects a history of gastrointestinal disease
Subjects less than four weeks from allogenic or autologous stem cell transplant infusion
Clareo Health | A Study of BMS-863233 in Patients With Hematologic Cancer
